Novartis All Smiles After Kisqali OS Success In MONALEESA-2
Head-To-Head Study With Ibrance Planned
Executive Summary
After the presentation of stellar long-term survival data at ESMO for Kisqali in women with HR+/HER2- advanced breast cancer, Novartis is planning to knock Pfizer's Ibrance off its CDK4/6 inhibitor perch with the help of a head-to-head trial.